A095700 Stock Overview
Operates as a biotechnology company that focuses on the development and commercialization of immunotherapies in South Korea and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Genexine, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩7,780.00 |
| 52 Week High | ₩12,300.00 |
| 52 Week Low | ₩5,840.00 |
| Beta | 0.94 |
| 11 Month Change | 10.20% |
| 3 Month Change | 9.27% |
| 1 Year Change | -21.89% |
| 33 Year Change | -88.25% |
| 5 Year Change | -79.44% |
| Change since IPO | -25.36% |
Recent News & Updates
We Think Genexine (KOSDAQ:095700) Has A Fair Chunk Of Debt
Jul 12
Genexine (KOSDAQ:095700) Has Debt But No Earnings; Should You Worry?
Mar 14Shareholder Returns
| A095700 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 10.0% | 3.2% | 2.9% |
| 1Y | -21.9% | 37.4% | 4.4% |
Return vs Industry: A095700 underperformed the KR Biotechs industry which returned 38% over the past year.
Return vs Market: A095700 underperformed the KR Market which returned 3.8% over the past year.
Price Volatility
| A095700 volatility | |
|---|---|
| A095700 Average Weekly Movement | 6.1% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in KR Market | 12.1% |
| 10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A095700 has not had significant price volatility in the past 3 months.
Volatility Over Time: A095700's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 86 | n/a | www.genexine.com |
Genexine, Inc., together with its subsidiaries, operates as a biotechnology company that focuses on the development and commercialization of immunotherapies in South Korea and internationally. The company develops its products through its hybrid Fc platform, a proprietary technology designed to develop long-acting protein drugs; and the DNA vaccine platform that is used to elicit immune responses in the human body to fight viral infection and cancer cells. Its product pipeline includes GX-H9, which is in Phase II and III clinical trials for the treatment of adult and pediatric growth hormone deficiency; GX-E4 that is in Phase III clinical trials for the treatment of anemia; GX-G3, which is in Phase II clinical trials to treat neutropenia; GX-I7, a product candidate in Phase I and II clinical trials to treat solid tumors, lymphopenia, and COVID-19; GX-P1, which is in Phase I clinical trials for the treatment of autoimmune diseases and transplantation; and GX-G6 that is in Phase II clinical trials for the treatment of diabetes.
Genexine, Inc. Fundamentals Summary
| A095700 fundamental statistics | |
|---|---|
| Market cap | ₩322.48b |
| Earnings (TTM) | -₩54.53b |
| Revenue (TTM) | ₩5.81b |
55.5x
P/S Ratio-5.9x
P/E RatioIs A095700 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A095700 income statement (TTM) | |
|---|---|
| Revenue | ₩5.81b |
| Cost of Revenue | ₩6.00b |
| Gross Profit | -₩196.75m |
| Other Expenses | ₩54.33b |
| Earnings | -₩54.53b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.32k |
| Gross Margin | -3.39% |
| Net Profit Margin | -938.81% |
| Debt/Equity Ratio | 23.8% |
How did A095700 perform over the long term?
See historical performance and comparison